| Medical and Health Sciences | Lifetime | 658 | CN 8 | 99.97 |
| Medical and Health Sciences | 2021-2025 | 444 | CN 50 | 99.90 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 31 | CN 1 | 99.88 |
| Epidemiology | Lifetime | 804 | CN 22 | 98.92 |
| Genetics | Lifetime | 648 | CN 9 | 98.44 |
| Cardiology and Cardiovascular Medicine | Lifetime | 800 | CN 3 | 98.31 |
| Nephrology | Lifetime | 328 | CN 11 | 97.20 |
| Obstetrics and Gynecology | Lifetime | 706 | CN 10 | 91.33 |
| Complementary and Alternative Medicine | Lifetime | 853 | CN 81 | 90.24 |
| Clinical Biochemistry | Lifetime | 792 | CN 15 | 79.40 |
| Hepatology | Lifetime | 995 | CN 63 | 68.77 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 27 | CN 1 | 99.74 |
| Genetics | 2021-2025 | 160 | CN 11 | 95.69 |
| Epidemiology | 2021-2025 | 581 | CN 60 | 94.65 |
| Surgery | 2021-2025 | 637 | CN 60 | 94.48 |
| Medical Physiology | 2021-2025 | 498 | CN 31 | 92.64 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 983 | CN 53 | 78.29 |
| Diabetes Management and Education | Lifetime | 14 | CN 1 | 99.63 |
| Diabetes Treatment and Management | Lifetime | 38 | CN 1 | 99.80 |
| Chronic Disease Management Strategies | Lifetime | 27 | CN 1 | 99.50 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 47 | CN 1 | 99.77 |
| Diabetes Management and Research | Lifetime | 65 | CN 1 | 99.66 |
| Diabetes and associated disorders | Lifetime | 90 | CN 1 | 99.39 |
| Metabolism, Diabetes, and Cancer | Lifetime | 85 | CN 1 | 99.56 |
| Liver Disease Diagnosis and Treatment | Lifetime | 400 | CN 16 | 99.42 |
| Pharmacology and Obesity Treatment | Lifetime | 48 | CN 1 | 99.22 |
| Pancreatic function and diabetes | Lifetime | 234 | CN 3 | 99.16 |
| Diet and metabolism studies | Lifetime | 542 | CN 10 | 99.00 |
| Diet, Metabolism, and Disease | Lifetime | 241 | CN 5 | 98.60 |
| Cardiovascular Health and Risk Factors | Lifetime | 101 | CN 7 | 98.36 |
| Cardiovascular Disease and Adiposity | Lifetime | 361 | CN 6 | 98.11 |
| Blood Pressure and Hypertension Studies | Lifetime | 622 | CN 5 | 98.25 |
| Chronic Kidney Disease and Diabetes | Lifetime | 382 | CN 17 | 97.96 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | Lifetime | 290 | CN 1 | 96.40 |
| Gestational Diabetes Research and Management | Lifetime | 533 | CN 11 | 96.91 |
| Hormonal Regulation and Hypertension | Lifetime | 931 | CN 16 | 96.59 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 873 | CN 23 | 96.59 |
| Lipoproteins and Cardiovascular Health | Lifetime | 909 | CN 13 | 96.64 |
| Medication Adherence and Compliance | Lifetime | 404 | CN 4 | 94.63 |
| Renin-Angiotensin System Studies | Lifetime | 778 | CN 22 | 93.78 |
| Lipid metabolism and disorders | Lifetime | 839 | CN 39 | 92.41 |
| Renal function and acid-base balance | Lifetime | 987 | CN 6 | 92.48 |
| Apelin-related biomedical research | Lifetime | 856 | CN 71 | 84.70 |
| Diabetes Management and Research | 2021-2025 | 31 | CN 1 | 99.42 |
| Diabetes Treatment and Management | 2021-2025 | 46 | CN 1 | 99.53 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 31 | CN 1 | 98.97 |
| Diabetes Management and Education | 2021-2025 | 33 | CN 1 | 97.43 |
| Pancreatic function and diabetes | 2021-2025 | 103 | CN 2 | 97.73 |
| Chronic Disease Management Strategies | 2021-2025 | 87 | CN 6 | 96.67 |
| Diet and metabolism studies | 2021-2025 | 262 | CN 36 | 97.06 |
| Diabetes and associated disorders | 2021-2025 | 109 | CN 4 | 97.19 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 111 | CN 20 | 96.67 |
| Chronic Kidney Disease and Diabetes | 2021-2025 | 342 | CN 56 | 92.42 |
| Pharmacology and Obesity Treatment | 2021-2025 | 165 | CN 5 | 87.48 |
| Cardiovascular Health and Risk Factors | 2021-2025 | 902 | CN 204 | 76.57 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | 2021-2025 | 749 | CN 84 | 65.26 |
